APA (7th ed.) Citation

Rimmel, B., Bender, D., Enserro, D., Westin, S., Powell, M., Holman, L., . . . Mackay, H. (2025). 1115P NRG GY012: A randomized phase II study comparing single-agent cediranib with olaparib/durvalumab, cediranib/durvalumab, and olaparib/capivasertib in women with recurrent, persistent or metastatic endometrial cancer. Annals of Oncology, 36, S742. https://doi.org/10.1016/j.annonc.2025.08.1752

Chicago Style (17th ed.) Citation

Rimmel, B., et al. "1115P NRG GY012: A Randomized Phase II Study Comparing Single-agent Cediranib with Olaparib/durvalumab, Cediranib/durvalumab, and Olaparib/capivasertib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer." Annals of Oncology 36 (2025): S742. https://doi.org/10.1016/j.annonc.2025.08.1752.

MLA (9th ed.) Citation

Rimmel, B., et al. "1115P NRG GY012: A Randomized Phase II Study Comparing Single-agent Cediranib with Olaparib/durvalumab, Cediranib/durvalumab, and Olaparib/capivasertib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer." Annals of Oncology, vol. 36, 2025, p. S742, https://doi.org/10.1016/j.annonc.2025.08.1752.